000137689 001__ 137689
000137689 005__ 20240229112521.0
000137689 0247_ $$2doi$$a10.1093/neuonc/noy155
000137689 0247_ $$2pmid$$apmid:30252101
000137689 0247_ $$2ISSN$$a1522-8517
000137689 0247_ $$2ISSN$$a1523-5866
000137689 0247_ $$2altmetric$$aaltmetric:48866207
000137689 037__ $$aDKFZ-2018-01566
000137689 041__ $$aeng
000137689 082__ $$a610
000137689 1001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b0$$eFirst author$$udkfz
000137689 245__ $$aDNA-methylation profiling is a method of choice for molecular verification of pediatric WNT activated medulloblastomas.
000137689 260__ $$aOxford$$bOxford Univ. Press$$c2019
000137689 3367_ $$2DRIVER$$aarticle
000137689 3367_ $$2DataCite$$aOutput Types/Journal article
000137689 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1566461660_7434
000137689 3367_ $$2BibTeX$$aARTICLE
000137689 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137689 3367_ $$00$$2EndNote$$aJournal Article
000137689 520__ $$aWNT activated medulloblastoma (WNT MB) represent a well-characterized molecular variant accounting for 10-15% of all MB and is associated with a favorable clinical outcome. Patients with localized WNT MBs could benefit from de-intensification of combined treatment, which would require an accurate diagnosis of these tumors. However, despite the presence of molecular features related with a WNT MB signature (nuclear ß-catenin immunoexpression, CTNNB1 mutation and monosomy 6), a prompt and reliable diagnostic verification of these tumors is not yet feasible.In the current study, we analyzed 78 samples of WNT MB treated in a single institute through genome-wide DNA methylation and targeted next generation sequencing to elaborate an optimal method for WNT MB molecular verification.We found that DNA-methylation profiling discloses significant advantages for molecular diagnostic of WNT MB. All other 'routine' methods applied such as ß-catenin immunohistochemistry, CTNNB1 mutation analysis, and detection of monosomy 6 failed to identify all WNT MB cases. Survival analysis revealed that application of a reduced radiotherapy protocol for WNT MB treatment had no influence on patients' survival. Only one patient died due to local relapse but recurrent tumor was pathologically and molecularly diagnosed as a secondary glioblastoma.1. DNA methylation analysis should be considered as a method of choice for further clinically relevant stratification of WNT MB and for correct diagnosis of the recurrent tumors. 2. WNT MB patients with localized disease could benefit from treatment de-intensification.
000137689 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000137689 588__ $$aDataset connected to CrossRef, PubMed,
000137689 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b1$$udkfz
000137689 7001_ $$aZheludkova, Olga$$b2
000137689 7001_ $$aGolanov, Andrey$$b3
000137689 7001_ $$0P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aStichel, Damian$$b4$$udkfz
000137689 7001_ $$0P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aSchrimpf, Daniel$$b5$$udkfz
000137689 7001_ $$aRyzhova, Marina$$b6
000137689 7001_ $$aPotapov, Alexander$$b7
000137689 7001_ $$0P:(DE-He78)e1415e1a2d46648d49fa06d0c58b90df$$aHabel, Antje$$b8$$udkfz
000137689 7001_ $$0P:(DE-He78)b6273c0ba3ae37a4d3d1c6b084797f2e$$aMeyer, Jochen$$b9$$udkfz
000137689 7001_ $$0P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c$$aLichter, Peter$$b10$$udkfz
000137689 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b11$$udkfz
000137689 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b12$$udkfz
000137689 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b13$$udkfz
000137689 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b14$$eLast author$$udkfz
000137689 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noy155$$n2$$p214-221$$tNeuro-Oncology$$v21$$x1523-5866$$y2019
000137689 909CO $$ooai:inrepo02.dkfz.de:137689$$pVDB
000137689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000137689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000137689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000137689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000137689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e1415e1a2d46648d49fa06d0c58b90df$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000137689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b6273c0ba3ae37a4d3d1c6b084797f2e$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000137689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000137689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000137689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000137689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000137689 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000137689 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000137689 9141_ $$y2019
000137689 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000137689 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000137689 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000137689 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000137689 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137689 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000137689 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000137689 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000137689 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000137689 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000137689 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000137689 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lNeuropathologie$$x0
000137689 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lMolekulare Genetik$$x1
000137689 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x2
000137689 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000137689 980__ $$ajournal
000137689 980__ $$aVDB
000137689 980__ $$aI:(DE-He78)B300-20160331
000137689 980__ $$aI:(DE-He78)B060-20160331
000137689 980__ $$aI:(DE-He78)B062-20160331
000137689 980__ $$aI:(DE-He78)L101-20160331
000137689 980__ $$aUNRESTRICTED